Cecilia Brown

Cecilia Brown is an assistant editor for Mashup Media, the parent company of Cancer Nursing Today. Cecilia is a medical writer and editor with over four years of experience in publishing and journalism, as well as several years of research experience. She can be reached at CBrown@mashupmd.com.

Articles by Cecilia Brown

Cecilia BrownConferences | December 9, 2022
No graft-versus-host disease (GVHD) occurred in patients with multiple myeloma (MM) who received allogeneic CAR-T therapy.
Read More
Cecilia BrownConferences | December 9, 2022
Around 25% of patients with high-risk MDS or AML who received venetoclax plus azacitidine maintenance developed chronic GVHD.
Cecilia BrownConferences | December 9, 2022
Frailty is strongly associated with worse survival outcomes in patients with chronic graft-versus-host disease (GVHD).
Cecilia BrownConferences | December 9, 2022
No GVHD exacerbations occurred with a BCMA-directed CAR-T in patients with multiple myeloma.
Cecilia BrownConferences | December 9, 2022
Donor-derived, CD7-directed, CAR T-cell therapy had “encouraging activity” but led to reversible GVHD in 40% of patients.
Cecilia BrownConferences | December 9, 2022
Around one-third of patients with TP53-mutated acute leukemias or MDS who underwent HSCT developed chronic GVHD.
Cecilia BrownConferences | December 9, 2022
No moderate-to-severe chronic GVHD occurred in patients with high-risk hematologic malignancies who received Orca-Q.
Cecilia BrownConferences | December 9, 2022
Fludarabine plus busulfan led to lower rates of grade III-IV acute GVHD than cyclophosphamide plus busulfan.
Cecilia BrownConferences | December 9, 2022
Belumosudil combination therapy in a real-world setting “appears safe, tolerable, and effective” for chronic GVHD.
Cecilia BrownConferences | December 9, 2022
Patients receiving allogeneic HSCT face an average of $1 million in transplant-related costs throughout their lifetimes.
Cecilia BrownConferences | December 9, 2022
Extensive chronic GVHD occurred in 15% of patients with ALL within 2 years of undergoing allogeneic HSCT.
Cecilia BrownConferences | December 9, 2022
Patients with closely matched donors who received one type of post-transplant regimen had lower rates of GVHD.
Cecilia BrownConferences | October 5, 2022
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
Cecilia BrownConferences | October 5, 2022
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
Cecilia BrownConferences | October 5, 2022
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Cecilia BrownConferences | October 5, 2022
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Cecilia BrownConferences | October 5, 2022
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Cecilia BrownConferences | October 5, 2022
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
Cecilia BrownConferences | October 5, 2022
Patients with CMML who developed GVHD after transplant were less likely to relapse than patients who did not develop GVHD.
Cecilia BrownConferences | October 5, 2022
More than half of patients receiving haploidentical HSCT had GVHD, but age was the only predictive factor for survival.